Nirmatrelvir: all 28 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe DiseaseRecruitingNCT05261139Phase 3
• Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)RecruitingNCT05041907Phase 2
• Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingNCT02735707Phase 3
• Paxlovid for Treatment of Long CovidCompletedNCT05576662Phase 2Results posted
• A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/RitonavirCompletedNCT05567952Phase 2Results posted
• A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney DiseaseTerminatedNCT05487040Phase 1Results posted
• A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating WomenCompletedNCT05441215Phase 1Results posted
• A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune SystemCompletedNCT05438602Phase 2Results posted
• A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.CompletedNCT05339334Phase 1Results posted
• Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy ParticipantsCompletedNCT05263921Phase 1Results posted
• Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet FormulationCompletedNCT05263895Phase 1Results posted
• Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult ParticipantsCompletedNCT05129475Phase 1Results posted
• PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy ParticipantsCompletedNCT05064800Phase 1Results posted
• A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 InfectionCompletedNCT05047601Phase 2/3Results posted
• Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy ParticipantsCompletedNCT05032950Phase 1Results posted
• Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).TerminatedNCT05011513Phase 2/3Results posted
• Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332CompletedNCT05005312Phase 1Results posted
• Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With RitonavirCompletedNCT04962230Phase 1Results posted
• Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy ParticipantsCompletedNCT04962022Phase 1Results posted
• EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19CompletedNCT04960202Phase 2/3Results posted
• Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.CompletedNCT04909853Phase 1Results posted
• STUDY OF PF-07321332 IN HEALTHY PARTICIPANTSCompletedNCT04756531Phase 1Results posted
• A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.CompletedNCT05668091Phase 2
• A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19WithdrawnNCT05545319Phase 2
• Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)CompletedNCT05491330Phase 1
• A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19TerminatedNCT05386472Phase 1
• Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.WithdrawnNCT05178654Phase 1
• Australasian COVID-19 Trial (ASCOT) ADAptive Platform TrialActive, not recruitingNCT04483960Phase 3

← Nirmatrelvir overview